Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Verizon Communications Inc (VZ) Price & Performance

Citius Pharmaceuticals IncTrade
Verizon Communications IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Verizon Communications Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.69 (market cap $20.01M), while Verizon Communications Inc trades at $46.89 (market cap $196.40B). The key difference: Verizon Communications Inc is far larger — about 9815.1× Citius Pharmaceuticals Inc's market cap, and Verizon Communications Inc pays a 5.99% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRVZ
Market Cap
$20.01M$196.40B
Sector
HealthMedia
52-Week High
$1.82$51.38
52-Week Low
$0.48$38.40
Enterprise Value
$16.23M$383.10B
Volume
22,584,735
Dividend Yield
5.99%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

Verizon Communications Inc

Verizon (VZ) trades at $47.03, down 0.06% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $49.69. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.30 surpassing the $1.27 estimate. The company maintains strong cash flow from operations at $37.14 billion in 2025 and a healthy dividend yield, supported by a $0.71 per share payout scheduled for August 2026.

VZ presents a value opportunity with a low P/E of 12.31 and stable revenue around $138 billion, though competitive pressures from new entrants like SpaceX's Starlink and high debt levels pose risks. Analyst sentiment is mixed with 36.7% buy ratings, but fundamentals suggest resilience for income-focused investors seeking telecom exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Verizon Communications Inc

Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.

Read more on VZ